Royalty Reports. During the Agreement Term, following the first sale of a Product giving rise to Net Sales, within ​ days after the end of each Calendar Quarter, Vertex will deliver a report to CRISPR specifying on a Product-by-Product and country-by-country basis: # gross sales in the relevant Calendar Quarter, # Net Sales in the relevant Calendar Quarter, including an accounting of deductions applied to determine Net Sales; # a summary of the then-current exchange rate methodology then in use by Vertex, and # royalties payable on such Net Sales. All royalty payments due under [Section 6.4.1] or [Section 6.6.2] for each Calendar Quarter will be due and payable within ​ days after Vertex’s delivery of the applicable report under this [Section 6.4.5].

Royalty Reports. Takeda shall calculate all amounts payable to Poseida pursuant to this [Section 6.6] at the end of each Calendar Quarter. Within […​…] of the end of each Calendar Quarter, Takeda shall provide to Poseida a statement of the amount of Net Sales of each Licensed Product in each country or other jurisdiction in the Territory during the applicable Calendar Quarter, in sufficient detail to permit confirmation of the accuracy of the royalty payment made, the gross sales and Net Sales of Licensed Products by country or jurisdiction, as applicable (including the deductions from gross sales to arrive at Net Sales and any withholding taxes required to be withheld hereunder, if any) and a calculation of the amount of royalty payment due on such Net Sales for such Calendar Quarter. If no royalties are due for any Calendar Quarter hereunder Takeda will so report. Any such information shared by Takeda under this [Section 6.6(d)] shall be deemed Takeda’s Confidential Information.

Royalty Reports. Beginning with the First Commercial Sale of a Licensed Product, within [ * ] following the end of each Calendar Quarter, Licensee shall make quarterly royalty reports to Institute on or before each February 28, May 31, August 31 and November 30 of each year. Each royalty report will cover the Licensee’s most recently completed Calendar Quarter and will show: # the amount

Royalty Reports. No later than ​ after the end of each Calendar Quarter during which any Royalties are owed, CANbridge will submit to LogicBio a written report of Net Sales of Products sold, in the currency for which such Products were sold, by or on behalf of CANbridge and its Affiliates and Sublicensees during such Calendar Quarter, and the royalties payable on such Net Sales ​ paid hereunder.

Royalty Reports. Following the first commercial sale of a Licensed Product, Cell Medica shall submit to Baylor within sixty (60) days after March 31, June 30, September 30 and December 31, a written report with respect to such Licensed Product on a form provided by Baylor (a current version of which is attached as [Schedule E]) setting forth for such calendar quarter at least the following information, to the extent Cell Medica, its Affiliates, and/or sublicensees possesses or can obtain such information:

Royalty Reports. Commencing with the first day of the calendar quarter following the calendar quarter in which the obligation of the Licensee to pay running royalty payments pursuant to Section 5.7 of this Agreement is triggered, the Licensee shall provide to UABRF a written report setting forth all applicable information specified in [Exhibit E], which such report shall accompany the payment of all running royalties due to be paid to UABRF by the Licensee with respect to the preceding calendar quarter. Reports furnished must include the calculation of running royalties by Licensed Product and by country/jurisdiction and must include the rate of currency conversion and the date such conversion was calculated as described in Section 5.13 of this Agreement, all in substantially the format set forth in [Exhibit E]. If the Licensee is required to pay an annual minimum royalty payment, at the time such payment is made, the Licensee shall also furnish a written report providing, to the extent not already provided to UABRF, all of the information required to be set forth in the quarterly reports discussed above and the additional amount being paid by the Licensee which accompanies the report, being the difference between aggregate running royalty payment actually paid to UABRF in that calendar year and the minimum payment required to be paid.

Royalty Reports. Following the completion of each Royalty Quarter, Seller shall promptly (but in no event more than ten (10) days after Seller receives a Novartis Royalty Report or a Palobiofarma Royalty Report, as applicable, for such Royalty Quarter) deliver to Purchaser a complete copy of such Novartis Royalty Report or Palobiofarma Royalty Report for the applicable Royalty Quarter. With respect to any Palobiofarma Products or Terminated Novartis Licensed Products that are developed internally and sold by Seller or Third Parties on Seller’s behalf, Seller shall prepare and deliver quarterly Royalty Reports to Purchaser detailing the quarterly Net Sales thereof and the corresponding royalties payable to Purchaser (and if such Products are sold directly by Seller remit such royalties to Purchaser) within forty-five days after the end of each Royalty Quarter.

Royalty Reports. Beginning with the First Commercial Sale of an Licensed Product, within ​ following the end of each Calendar Quarter, Licensee shall make quarterly royalty reports to Institute on or before each February 28, May 31, August 31 and November 30 of each year. Each royalty report will cover the Licensee’s most recently completed Calendar Quarter and will show: # the amount invoiced for Sales and Net Sales of Licensed Products that are Sold during the most recently completed calendar quarter; # the ​ Licensed Product that is Sold on a country by country basis; # the Earned Royalties, in U.S. dollars, payable with respect to Sales of Licensed Products; # the ​ Earned Royalty; # a ​ to calculate Net Sales; and # the exchange rates used.

Royalty Reports. Following the first sale of a Product giving rise to Net Sales and continuing for the remainder of the Royalty Term, # within ​ after the end of each Calendar Quarter, [[MyoKardia:Organization]] will deliver a report to Fulcrum specifying on a Product-by-Product and country-by-country basis, [[MyoKardia:Organization]]’s preliminary, non-binding, good faith estimates of the royalties payable to Fulcrum on Net Sales of such Products in such countries, and # within ​ after the end of each Calendar Quarter, [[MyoKardia:Organization]] will deliver a report to Fulcrum specifying on a Product-by-Product and country-by-country basis: # Net Sales in the relevant Calendar Quarter; # to the extent such Net Sales include sales not denoted in Dollars, a summary of the then-current exchange rate methodology then in use by [[MyoKardia:Organization]]; # a calculation of any adjustments to such royalties under [Section 6.4.4(a)] (Valid Claim Adjustment); # the applicable Cardiomyopathy Milestone Target(s) directed against such Product and the applicable Royalty Rate(s) under this Agreement for such Net Sales; and # a calculation of the final royalties payable on such Net Sales. All royalty payments due under this Section 6.4 (Royalties) for each Calendar Quarter will be due and payable within ​ after the end of each Calendar Quarter. [[MyoKardia:Organization]]’s reports delivered to Fulcrum under this [Section 6.4.6] (Royalty Reports) will be [[MyoKardia:Organization]]’s Confidential Information under this Agreement.

Royalty Reports. Following the first sale of a Product giving rise to Net Sales and continuing for the remainder of the Royalty Term, # within ​ after the end of each Calendar Quarter, Acceleron will deliver a report to Fulcrum specifying on a Product-by-Product and country-by-country basis, Acceleron’s preliminary, non-binding, good faith estimates of the royalties payable to Fulcrum on Net Sales of such Products in such countries, and # within ​ after the end of each Calendar Quarter, Acceleron will deliver a report to Fulcrum specifying on a Product-by-Product and country-by-country basis: # Net Sales in the relevant Calendar Quarter; # to the extent such Net Sales include sales not denoted in Dollars, a summary of the then-current exchange rate methodology then in use by Acceleron, # a calculation of any adjustments to such royalties under [Section 6.3.3] (Royalty Adjustments), # the applicable Royalty Rate(s) under this Agreement for such Net Sales, and # a calculation of the final royalties payable on such Net Sales. All royalty payments due under this [Section 6.3] (Royalties) for each Calendar Quarter will be due and payable within ​ after the end of each Calendar Quarter. Acceleron’s reports delivered to Fulcrum under this [Section 6.3.4] (Royalty Reports) will be Acceleron’s Confidential Information under this Agreement.